Investment view: Despite all the crowing, it pays to be cautious

GlaxoSmithKline Our view: Keep buying

Price: 1406.5p (-1.5p)

Astrazeneca Our view: Hold

Price: 2896.5p (+12p)

After the gloom of the double-dip recession, the Government was crowing yesterday thanks to the economy apparently roaring back with growth of 1 per cent in the third quarter. So, is it time to dive into the stock market for some of the more risky plays out there?

Certainly some investors did. The FTSE 100 reacted with a shrug of the shoulders to post a small gain, but these days it is an international index dependent on commodities, international finance and the like.

The FTSE 250 index of second-tier, much more UK-focused companies, posted a very solid gain, suggesting the market looked at the figures with starry eyes.

But there are grounds for caution. The GDP figure was flattered by a number of one-offs and confidence remains pretty fragile.

That's why I'm going to look at GlaxoSmithKline and AstraZeneca, generally considered defensive plays valued more for the ability to pay solid dividends than for runaway growth.

Astra, which posted third-quarter results yesterday, isn't quite as defensive as it once was. The Anglo-Swedish drugs group has been battered as patents have run out on key treatments with a lack of new innovations to replace them. Third-quarter sales fell to $6.2bn (£3.8bn) against $8.2bn for the same period in 2011. That's down by 19 per cent, 15 per cent after smoothing for currency fluctuations. Operating profits were also hit, coming in at $2.2bn from $4.3bn, a tumble of 49 per cent (47 per cent at constant currencies).

There were a couple of disposals, but the problem was that a number of key treatments no longer have patent protection in the lucrative US market.

While the numbers might look scary, the problem is priced into the shares, which trade on just 7.8 times this year's forecast earnings, while yielding a shade above 6 per cent. Even with the reduction in earnings, the payout is twice covered.

Astra, it's true, suspended plans for share buybacks to give it flexibility to do deals and buy more treatments, when Pascal Soriot was hired to replace the ousted David Brennan as chief executive. The good thing is most analysts believe the divvy is stable. And it's very attractive.

I'm usually wary of mergers and acquisitions, but Astra's could use a shot in the arm from somewhere. At the very beginning of July I said the innovative tie-up with US peer Bristol-Myers Squib for the £4.5bn takeover of US biotech Amylin, with its potential blockbuster diabetes drugs, made it worth a punt. At the time it stood at 2,882p. The shares are little changed since then. I'm inclined to stick with them, but wouldn't buy more until we've seen more detail on Mr Soriot's plans. Hold.

GlaxoSmithKline is in a much happierplace, with less of a reliance on blockbuster drugs and a useful place in the consumer healthcare business in emerging markets, where the demographics are very much in its favour.

The shares are down a shade from where I said buy at 1,427p on 17 April, despite a run of resilient financial statements which suggest that everything at GSK is running smoothly. Perhaps the explanation is that investors are shunning safe, boring-looking big pharma stocks like GSK in favour of more excitement. I can't blame them.

But I'm not convinced that either the British or the global economies are out of the woods. You only need another wobble in the eurozone, more stupidity in the US congress over that country's debt mountain, or any number of other possible shocks to knock things sideways.

As such, I'd want a quality, defensive, stock like GSK on my side. On 12 times this year's forecast earnings it's no screaming bargain. But quality costs money, and the 5 per cent forecast yield is well worth having.

Start your day with The Independent, sign up for daily news emails
Sport
Tim Sherwood raises his hand after the 1-0 victory over Stoke
footballFormer Tottenham boss leads list of candidates to replace Neil Warnock
Arts and Entertainment
L to R: Hawkeye (Jeremy Renner), Captain America (Chris Evans) & Black Widow (Scarlett Johansson) in Avengers Assemble
film
News
Nigel Farage celebrates with a pint after early local election results in the Hoy and Helmet pub in South Benfleet in Essex
peopleHe has shaped British politics 'for good or ill'
News
news
PROMOTED VIDEO
News
i100
Travel
Suite dreams: the JW Marriott in Venice
travelChic new hotels in 2015
Arts and Entertainment
Sink the Pink's 2013 New Year's Eve party
musicFour of Britain's top DJs give their verdict on how to party into 2015
Sport
Yaya Sanogo, Mats Hummels, Troy Deeney and Adnan Januzaj
footballMost Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Selby Jennings: VP/SVP Credit Quant- NY- Investment Bank

Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...

Selby Jennings: Quantitative Research | Equity | New York

Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...

Selby Jennings: SVP Model Validation

Not specified: Selby Jennings: SVP Model Validation This top tiered investment...

Selby Jennings: Oil Operations

Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...

Day In a Page

Aren’t you glad you didn’t say that? The worst wince-and-look-away quotes of the year

Aren’t you glad you didn’t say that?

The worst wince-and-look-away quotes of the year
Hollande's vanity project is on a high-speed track to the middle of nowhere

Vanity project on a high-speed track to nowhere

France’s TGV network has become mired in controversy
Sports Quiz of the Year

Sports Quiz of the Year

So, how closely were you paying attention during 2014?
Alexander Armstrong on insulting Mary Berry, his love of 'Bargain Hunt', and life as a llama farmer

Alexander Armstrong on insulting Mary Berry and his love of 'Bargain Hunt'

From Armstrong and Miller to Pointless
Sanchez helps Gunners hold on after Giroud's moment of madness

Sanchez helps Gunners hold on

Olivier Giroud's moment of madness nearly costs them
A Christmas without hope: Fears grow in Gaza that the conflict with Israel will soon reignite

Christmas without hope

Gaza fears grow that conflict with Israel will soon reignite
After 150 years, you can finally visit the grisliest museum in the country

The 'Black Museum'

After 150 years, you can finally visit Britain's grisliest museum
No ho-ho-hos with Nick Frost's badass Santa

No ho-ho-hos with Nick Frost's badass Santa

Doctor Who Christmas Special TV review
Chilly Christmas: Swimmers take festive dip for charity

Chilly Christmas

Swimmers dive into freezing British waters for charity
Veterans' hostel 'overwhelmed by kindness' for festive dinner

Homeless Veterans appeal

In 2010, Sgt Gary Jamieson stepped on an IED in Afghanistan and lost his legs and an arm. He reveals what, and who, helped him to make a remarkable recovery
Isis in Iraq: Yazidi girls killing themselves to escape rape and imprisonment by militants

'Jilan killed herself in the bathroom. She cut her wrists and hanged herself'

Yazidi girls killing themselves to escape rape and imprisonment
Ed Balls interview: 'If I think about the deficit when I'm playing the piano, it all goes wrong'

Ed Balls interview

'If I think about the deficit when I'm playing the piano, it all goes wrong'
He's behind you, dude!

US stars in UK panto

From David Hasselhoff to Jerry Hall
Grace Dent's Christmas Quiz: What are you – a festive curmudgeon or top of the tree?

Grace Dent's Christmas Quiz

What are you – a festive curmudgeon or top of the tree?
Nasa planning to build cloud cities in airships above Venus

Nasa planning to build cloud cities in airships above Venus

Planet’s surface is inhospitable to humans but 30 miles above it is almost perfect